Moreno Arrones, O. M.Béa Ardebol, S.Mayo Martinez, F.Pérez Pastor, G.Torres Navarro, I.Bonfill Ortí, MontserratDeza, G.Ruiz Salas, V.Masferrer, E.Feal, C.Turrión Merino, L.Toll, A.Yébenes, M.Galiano Mejías, S.Jaka, A.Ferrandiz Pulido, C.Florez, A.Hernández Hernández, N.Fernández de Misa, R.Rios Buceta, L.Sanmartin, O.2024-02-162024-02-162023-07-010001-7310https://hdl.handle.net/2445/207723Basal cell carcinoma (BCC) is the most prevalent cancer. A minority of BCCs have an aggressive behaviour (laBCC) and may require hedgehog pathway inhibitors such as sonidegib as its treatment. Objective: To describe the use of sonidegib in a large number of patients and provide more data on its real-life efficacy and safety profile.Methods: We conducted a retrospective and multicentric study that included patients treated with sonidegib. Epidemiological, effectiveness and safety data were collected.Results: A total of 82 patients with a mean age of 73.9 years were included. Ten patients had Gorlin syndrome. Median treatment duration was 6 months. Median follow-up duration was 34.2 months. Globally, 81.7% of the patients showed clinical improvement (52.4% partial response and 29.3% complete response), 12.2% clinical stability and 6.1% disease progression. There was no statistically significant difference in clinical improvement between the 24 h and 48 h sonidegib posology. After 6 months of treatment, 48.8% of the patients discontinued sonidegib. Prior vismodegib treatment and recurrent primary BCC were associated with a poorer response to sonidegib. At 6 months of treatment, 68.3% of the patients experienced at least one adverse effect. Conclusion: Sonidegib shows good effectiveness and acceptable safety profile in usual clinical practice.& COPY; 2023 AEDV. Published by Elsevier Espan & SIM;a, S.L.U.This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).7 p.application/pdfengcc by-nc-nd (c) Moreno Arrones, O. M. et al., 2023http://creativecommons.org/licenses/by-nc-nd/3.0/es/Medicaments antineoplàsticsCàncer de pellAntineoplastic agentsSkin cancerinfo:eu-repo/semantics/article2023-09-12info:eu-repo/semantics/openAccess37302483